IPFXU Inflection Point Acquisition Corp. VI

Price Chart

Executive Summary

Inflection Point Acquisition Corp. VI (IPFX) announced a definitive business combination agreement with Quantum Space, LLC, a space defense and orbital mobility company. The transaction values Quantum Space at a $600M pre-money equity value, with a post-transaction equity value of approximately $1.2B, and includes a $300M PIPE investment anchored by Inflection Point Asset Management. The combined company expects to list on Nasdaq under 'QSPC' in Q4 2026, with proceeds funding accelerated production of the Ranger spacecraft platform.

Key Financial Metrics

Actionable Insight

Key Facts

• Quantum Space pre-money equity value of $600M; post-transaction equity value ~$1.2B assuming 0% redemptions.
• $300M convertible PIPE at $12/share anchored by Inflection Point Asset Management.
• Existing Quantum Space equity holders expected to retain ~50% ownership at close.
• Combined company expects ~$533M pro forma cash to balance sheet (incl. $253M SPAC trust, $300M PIPE, less $20M expenses).
• Transaction expected to close in Q4 2026, subject to IPFX stockholder approval and customary conditions.
• Quantum Space has existing contracts with U.S. Space Force and AFRL, active proposals with DoW and DARPA, and eligibility under Space Force's $6.2B Andromeda IDIQ vehicle.
• Projected 2026E revenue of $23.6M (22% gross margin) and 2027E revenue of $60.6M (23% gross margin).
• Ranger spacecraft platform still in development — not yet manufactured, operated, or sold.
• No specific funding allocated to Quantum Space under the Andromeda contract as of filing date.

Financial Impact

Transaction implies ~$1.2B post-money equity value; $300M PIPE at $12/share; pro forma cash ~$533M; projected 2026E revenue $23.6M, 2027E $60.6M.

Risk Factors

• Ranger platform is still in development and has not been manufactured, operated, or sold — significant execution risk.
• Quantum Space has a history of losses and projects negative EBITDA of -$40.9M in 2026E and -$32.7M in 2027E.
• No specific funding allocated under the $6.2B Andromeda IDIQ contract — award eligibility does not guarantee revenue.
• SPAC shareholder redemptions could materially reduce pro forma cash below the $533M estimate.
• Projected financials are management estimates, not audited, and subject to significant uncertainty.
• Full-ratchet anti-dilution provisions on the Series A Preferred and warrants could further dilute common shareholders.

Market Snapshot

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

US Market Status

Related Tickers